Loading...
XNAS
IRMD
Market cap1.23bUSD
Jul 09, Last price  
98.04USD
1D
1.80%
1Q
4.97%
Jan 2017
783.24%
IPO
989.33%
Name

IRadimed Corp

Chart & Performance

D1W1MN
XNAS:IRMD chart
P/E
55.75
P/S
14.95
EPS
1.76
Div Yield, %
1.23%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
21.45%
Revenues
84m
+14.43%
7,685,06111,340,09715,653,05731,593,72032,496,54823,081,59230,438,98338,517,14131,717,37241,814,58153,303,14565,562,29673,242,12183,814,000
Net income
22m
+16.88%
966,0851,936,8902,050,3667,529,9207,214,545499,7646,303,4509,630,9591,369,0019,325,47112,828,48717,192,77619,234,02622,480,000
CFO
25m
-2.64%
1,509,1561,474,3972,585,7207,649,3309,406,3203,415,9187,376,01510,232,7335,817,49611,258,15610,042,71113,465,01225,624,46324,947,000
Dividend
Dec 17, 20250.5 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
IPO date
Jul 16, 2014
Employees
123
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT